April 13, 2021
The Centers for Disease Control and Prevention (CDC) and the Federal Drug Administration (FDA) issued a joint statement today recommending a pause in what they’ve been touting as a “safe and effective” COVID-19 vaccine produced by Johnson and Johnson (J&J).
The pause recommendation is in response to six cases, all women between the ages of 18 and 48, “of a rare and severe type of blood clot in individuals after receiving the J&J vaccine.”
In the statement, agency representatives say, “CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.”
You can read the full statement, here: https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html
